Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes

Approximately 20% of patients with TP53-mutant myelodysplastic syndromes (MDS) achieve complete remission (CR) with hypomethylating agents. Eprenetapopt (APR-246) is a novel, first-in-class, small molecule that restores wild-type p53 functions in TP53-mutant cells. METHODS: This was a phase Ib/II st...

Descripción completa

Detalles Bibliográficos
Autores principales: Sallman, David A., DeZern, Amy E., Garcia-Manero, Guillermo, Steensma, David P., Roboz, Gail J., Sekeres, Mikkael A., Cluzeau, Thomas, Sweet, Kendra L., McLemore, Amy, McGraw, Kathy L., Puskas, John, Zhang, Ling, Yao, Jiqiang, Mo, Qianxing, Nardelli, Lisa, Al Ali, Najla H., Padron, Eric, Korbel, Greg, Attar, Eyal C., Kantarjian, Hagop M., Lancet, Jeffrey E., Fenaux, Pierre, List, Alan F., Komrokji, Rami S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099410/
https://www.ncbi.nlm.nih.gov/pubmed/33449813
http://dx.doi.org/10.1200/JCO.20.02341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099410/
https://www.ncbi.nlm.nih.gov/pubmed/33449813
http://dx.doi.org/10.1200/JCO.20.02341

Ejemplares similares